ABSTRACT
The knowledge generated to deal with the devastating effects that COVID19 has allowed redesigning and producing new molecules that can be used as inhibitors of SARS-CoV-2. A prime example of these biomolecules is Nanobodies (Nbs), which contain autonomous function as single-domain antibodies maintaining high specificities for antigens. Moreover, they have small size and some of them present high physicochemical stability and structural resistance to high temperature and extreme pH conditions. Just one year after the beginning of the COVID-19 pandemic, there are several reports of the viral-host interaction blocking or neutralizing capacity of Nbs obtained from immunized animals or synthetic libraries. The molecular modifications of Nbs have led to powerful molecules with great potential as therapeutic or diagnostic tools. Undoubtedly, the knowledge generated thus far will pave the way for the faster development of Nbs against this and other emerging diseases. © 2022 Elsevier Inc. All rights reserved.